source
- Eli Lilly's retatrutide shows strong weight loss but no clear heart risk reduction in Phase 3 trialEli Lilly released new data from a Phase 3 trial of retatrutide, its next‑generation obesity drug. The study enrolled nearly 2,000 participants with severe obesity and existing heart disease, some…
- Most FDA-approved drugs meet postmarketing study requirements, and advisory panel backs two peptides for bulk compoundingA recent analysis published in JAMA Network Open found that nearly nine out of ten drugs approved by the U.S. Food and Drug Administration have completed their postmarketing requirements or commitm…